NEOG vs. CLDX, NTLA, MYGN, XRAY, MMSI, HAE, ICUI, QDEL, STAA, and VIVO
Should you be buying Neogen stock or one of its competitors? The main competitors of Neogen include Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), ICU Medical (ICUI), QuidelOrtho (QDEL), STAAR Surgical (STAA), and Meridian Bioscience (VIVO). These companies are all part of the "medical" sector.
Neogen (NASDAQ:NEOG) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.
96.7% of Neogen shares are owned by institutional investors. 0.7% of Neogen shares are owned by company insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Neogen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Neogen currently has a consensus price target of $22.50, indicating a potential upside of 29.83%. Celldex Therapeutics has a consensus price target of $62.17, indicating a potential upside of 39.51%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Neogen.
In the previous week, Neogen had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 7 mentions for Neogen and 5 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.94 beat Neogen's score of 0.90 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
Neogen has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
Neogen has a net margin of 0.17% compared to Celldex Therapeutics' net margin of -2,385.57%. Neogen's return on equity of 3.35% beat Celldex Therapeutics' return on equity.
Celldex Therapeutics received 275 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 75.06% of users gave Celldex Therapeutics an outperform vote while only 57.09% of users gave Neogen an outperform vote.
Summary
Neogen and Celldex Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Neogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEOG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
